Bioblast Pharma Announces Presentation at the 18th Annual Rodman & Renshaw Global Investment Conference on September 12, 2016

TEL AVIV, Israel, Sept. 07, 2016 -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced it will be featured as a presenting company at the 18^th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. 

Fredric Price, Executive Chairman, will provide an overview of the Company's business during the live presentation on Monday, September 12 at 2:10 PM and will be accompanied by Warren Wasiewski, MD, Chief Medical Officer and Chaime Orlev, who has recently joined Bioblast as Chief Financial Officer.

Event:  18^th Annual Rodman & Renshaw Global Investment Conference
Date:  September 12, 2016
Time:  2:10 PM
Location:  Kennedy II, 4^th floor, Lotte New York Palace Hotel in New York City

About Bioblast Pharma
Bioblast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases with a lead drug candidate, trehalose 90mg/mL solution, in Phase 2 development.  Bioblast was founded in 2012 and is traded on the NASDAQ under the symbol “ORPN”. For more information, please visit our website, www.bioblastpharma.com, the content of which is not incorporated herein by reference.

INVESTOR CONTACT: 
Matthew P. Duffy
Managing Director
LifeSci Advisors, LLC
Telephone:  212-915-0685